IPT Therapy for Cancer Treatment
IPT Therapy is for patients who have reached their maximum amount of chemo treatments. IPT allows cancer patients to get more chemo, safely.
Good candidates for IPT therapy are patients who have exhausted traditional chemotherapy treatment or who want a second line of defense against cancer. Since the doses are small and localized, patients may continue to receive chemo with up to 10 treatments of IPT.
When Chemo Stops Working
IPT or Insulin Potentiation Therapy is the use of insulin and low-dose chemotherapy to kill certain types of cancer cells. One of the many benefits of cancer care and of IPT therapy over traditional chemotherapy is its ability to target the cancer cells, with little, if any harm to the surrounding healthy cells. Because cancer cells feed on sugar and need it for survival, IPT uses a small amount of insulin administered to the patient, which immediately starves the cancer cells of the sugar they require for survival. This in turn causes the cells to open up, in an emergency effort to get sugar.
With the cancer cells starved and fully open to absorption, a small amount of chemo mixed with sugar is administered to the cells. Since the cancer cells are in their most vulnerable state, they more easily absorb the sugar mixed with the radioactive agent that poisons them.
Since the surrounding healthy cells are virtually unaffected, patients are able to avoid many of the unpleasant side effects that are common in traditional chemo treatments. Hair loss, nausea, weakness, and fatigue, rarely occur with IPT.
How IPT Therapy Works
At precisely the right moment after administering the insulin, when the cells are vulnerable and starving from the lack of sugar, the patient is given a small amount of chemo, followed quickly by a dose of sugar. Starving from the lack of glucose, the cancer cells absorb the largest portion of chemo as they feed on the sugar. Very little Chemo is left over to damage the surrounding healthy cells.
Due to insulin’s ability to potentiate chemotherapy, much less chemo is given to the patient while still being effective. With only a tenth of the amount of chemo used in conventional cancer treatment therapies, IPT makes it safer to use after conventional chemotherapy options have ended.
Note: It is important to properly support the liver during and after IPT due to the increased amount of toxins that will be passing thru the body. At Sunridge, we take a comprehensive approach to treating illness and the body. Our goal is to properly support the body so it can react using its own natural defense mechanisms. This provides our patients with the best opportunity of staying cancer-free and healthy long-term.
The Benefits of Insulin Potentiation Therapy
- More targeted to attack cancer cells, avoiding healthy cells
- Little to no side effects after treatment
- Use as a primary or secondary line of defense against cancer
- Uses only 1/10th the amount of chemo used in conventional therapies
- A continued treatment after conventional chemo has reached its maximum
- Avoid the side effects associated with traditional chemotherapy
- Can be used for patients who have reached their maximum of traditional chemo treatment
- Less toxic and hard on the immune system
- Kills less, if any healthy cells – more targeted
IPT Treatment at Sunridge
At Sunridge Medical, our highly-trained physicians are experts in providing an integrated approach to the treatment of cancer with IPT therapy. Our treatment plans are individualized and involve both traditional and alternative medicines. The physicians at Sunridge Medical have found that symptoms frequently can be improved and even reversed with our natural treatments. We take a holistic approach to patient care and strive not only to treat the disease, but also to alleviate symptoms, increase the quality of life and, most importantly, address the underlying cause of the disease.
References on IPT
The insulin-like growth factor (IGF) signaling system plays key roles in the establishment and progression of different types of cancer. In agreement with this idea, substantial evidence has shown that the type I IGF receptor (IGF-IR) and its primary ligand IGF-I are important for maintaining the survival of malignant cells of hematopoietic origin. In this review, we discuss the current understanding of the role of IGF-IR signaling in cancer with a focus on hematological neoplasms. We also address the emergence of IGF-IR as a potential therapeutic target for the treatment of different types of cancer including plasma cell myeloma, leukemia, and lymphoma.
